Cited by 182Dementia and Cognitive Impairment ResearchCerebrovascular and genetic disordersAlzheimer's disease research and treatments

Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults

Open access
Hedden, Trey, Mormino, Elizabeth C., Amariglio, Rebecca E., Younger, Alayna P., Schultz, Aaron P., Becker, J. Alex, Buckner, Randy L., Johnson, Keith A. +2 more·2012·The Journal of Neuroscience

Abstract

Amyloid burden and white matter hyperintensities (WMH) are two common markers of neurodegeneration present in advanced aging. Each represents a potential early indicator of an age-related neurological disorder that impacts cognition. The presence of amyloid is observed in a substantial subset of cognitively normal older adults, but the literature remains equivocal regarding whether amyloid in nondemented populations is deleterious to cognition. Similarly, WMH are detected in many nondemented older adults and there is a body of evidence indicating that WMH are associated with decreased executive function and other cognitive domains. The current study investigated amyloid burden and WMH in clinically normal older adult humans aged 65-86 (N = 168) and examined each biomarker's relation with cognitive domains of episodic memory, executive function, and speed of processing. Factors for each domain were derived from a neuropsychological battery on a theoretical basis without reference to the relation between cognition and the biomarkers. Amyloid burden and WMH were not correlated with one another. Age was associated with lower performance in all cognitive domains, while higher estimated verbal intelligence was associated with higher performance in all domains. Hypothesis-driven tests revealed that amyloid burden and WMH had distinct cognitive profiles, with amyloid burden having a specific influence on episodic memory and WMH primarily associated with executive function but having broad (but lesser) effects on the other domains. These findings suggest that even before clinical impairment, amyloid burden and WMH likely represent neuropathological cascades with distinct etiologies and dissociable influences on cognition.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.2462-12.2012

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • WMHs and Aβ are key drivers of cognitive decline in healthy older adults and both are considered biomarkers of preclinical dementia.

    “WMHs and Aβ are also key drivers of cognitive decline in healthy older adults, and both are considered biomarkers of preclinical dementia [6,7].”

    From Amyloid-PET and White Matter Hyperintensities Have Independent Effects on Baseline Cognitive Function and Synergistic Effects on Longitudinal Executive Function (2023) · cites this paper as [7]

    The Discussion (page not provided) reports associations between amyloid burden and memory and between WMHs and executive function in cognitively normal older adults. It describes these effects as small and notes that substantial age-related differences in cognition remain unexplained, so the cross-sectional findings do not establish that either is a key driver of decline. The Abstract calls both potential early indicators of age-related neurological disorders, but does not establish both as biomarkers of preclinical dementia. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Hedden, T., Mormino, E. C., Amariglio, R. E., Younger, A. P., Schultz, A. P., Becker, J. A., Buckner, R. L., Johnson, K. A., Sperling, R. A., & Rentz, D. M.
Affiliations
  • Harvard University (US)
  • Brigham and Women's Hospital (US)
  • Massachusetts General Hospital (US)
  • Howard Hughes Medical Institute (US)
Venue
The Journal of Neuroscience
Published
2012-11-14
Volume
32
Issue
46
Pages
16233-16242
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W2115296012
Cited by
182
References
82
Citations by year
2026: 6 · 2025: 6 · 2024: 7 · 2023: 7 · 2022: 9 · 2021: 7 · 2020: 18 · 2019: 12 · 2018: 18 · 2017: 16 · 2016: 13 · 2015: 25 · 2014: 21 · 2013: 17
FWCI
14.34
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
Funders
  • Howard Hughes Medical Institute
  • Massachusetts General Hospital (1S10RR023401, 1S10RR019307, 1S10RR023043, P41RR14075)
  • National Institutes of Health (1s10rr019307-01, RR14075, AG 036694, 1s10rr023043-01)
  • National Institute on Aging (K01AG040197, K24AG035007, R01AG027435, P50AG005134, P50 AG0513421, R01AG034556, P01AG036694, P30AG062421)
  • National Center for Research Resources (P41-RR-14075, RR 14075, S10-RR019307, S10-RR-023043, P41RR014075, 1S10RR0 23043, 1S10-RR019307, S10RR023401)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Neurology › Cerebrovascular and genetic disorders
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
amyloid burden, white matter hyperintensities, cognitively normal older adults, episodic memory, executive function, processing speed, neurodegeneration, verbal intelligence, age-related cognitive decline
MeSH terms
Aged, Aged, 80 and over, Amyloid, Amyloidosis, Brain, Cognition, Factor Analysis, Statistical, Female, Humans, Image Processing, Computer-Assisted, Magnetic Resonance Imaging, Male, Neuropsychological Tests, Psychomotor Performance, Anatomy, Cross-Sectional, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review